DDInter856 DDInter1296
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated hepar
Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function. As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options.
Nintedanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Danaparoid
Nintedanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Nintedanib {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Nintedanib {u} may lead to a major life threatening interaction when taken with {v} Lumacaftor
Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Nintedanib may lead to a major life threatening interaction when taken with Lomitapide
Nintedanib may lead to a major life threatening interaction when taken with Lumacaftor